Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532460 | 0.86 | LMNA (0.44) | LMNACYP3A4TSHRGRM2GRM3 | |
| SCHEMBL20897575 | 0.75 | CYP3A4 (0.38) | CYP3A4TSHRGRM2GRM3KCNH2 | |
| SCHEMBL4381803 | 0.75 | IDO1 (0.42) | CYP3A4TSHRGRM2GRM3KCNH2 | |
| SCHEMBL2134778 | 0.75 | ALDH1A1 (0.41) | LMNACYP3A4TSHRGRM2GRM3 | |
| SCHEMBL28781353 | 0.74 | KCNH2 (0.40) | LMNACYP3A4TSHRGRM2GRM3 | |
| SCHEMBL9303916 | 0.71 | ALDH1A1 (0.46) | GRM2GRM3ALDH1A1GAAMAPT | |
| SCHEMBL29100661 | 0.71 | ALDH1A1 (0.46) | LMNACYP3A4TSHRGRM2GRM3 | |
| SCHEMBL7052424 | 0.71 | — | — | |
| SCHEMBL10595586 | 0.71 | LMNA (0.54) | LMNAKCNH2ALDH1A1CYP2C19 | |
| SCHEMBL4569966 | 0.70 | KCNH2 (0.75) | LMNAKCNH2MAPTMRGPRX4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0661973-B1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | CHILDRENS MEDICAL CENTER (US) | 2006-06-21 | — | — | EP | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-20070218121-A1 | Compounds that inhibit caspase activity for treating glaucoma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| EP-0661973-B1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | CHILDRENS MEDICAL CENTER (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-0979073-A1 | NITROSYLATION TO INACTIVATE APOPTOTIC ENZYMES | The Children's Medical Center Corporation (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0661973-A4 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE. | CHILDRENS MEDICAL CENTER (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0581856-B1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | CHILDRENS MEDICAL CENTER (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1998043621-A1 | NITROSYLATION TO INACTIVATE APOPTOTIC ENZYMES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-10-08 | — | — | WO | disclosed |
| US-5801203-A | Nitroglycerine patch | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| US-5747545-A | SCREENING COMPOUNDS BY DETERMINING CHANNEL BLOCKING TIME | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| US-5455279-A | Regimen method of mediating neuronal damage using nitroglycerine | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0661973-A1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | The Children's Medical Center Corporation (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994006428-A1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5234956-A | Method of preventing NMDA receptor complex-mediated neuronal damage | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | LMNA 3003/4885CYP3A4 2764/4885TSHR 3708/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | LMNA 3003/4885CYP3A4 2764/4885TSHR 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.